Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 24 |
| Active Pipeline (Recruiting Now) | 16 (10) |
| Completed vs Stopped Early | 6 / 0 (0.0%) |
| Median Closed Actual Enrollment | 339 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Peking University People's Hospital | Beijing, Beijing Municipality | 6 |
| Zhejiang Provincial People's Hospital | Hangzhou, Zhejiang | 4 |
| Affiliated Hospital of Jiangsu University | Zhenjiang, Jiangsu | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07357831 | A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects | Phase III | COMPLETED |
| NCT06648772 | Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study | Phase III | COMPLETED |
| NCT06481085 | To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus | Phase II | COMPLETED |
| NCT06631170 | Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis | Phase III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Hangzhou Zhongmei Huadong Pharmaceutical Co Interactive Dossier, benchmark peers in Endocrinology, Obesity, and Metabolic, or review the Healthcare Price & Patent Cliff Crosswalk.